Company Monitoring Page for Novartis

latest headlines for company on cafepharma

Novartis’s iptacopan meets primary endpoint in Phase III PNH trial
Clinical Trials Arena
Thu, 04/27/23 - 10:30 am
Tags:
Novartis, clinical trials, PNH, iptacopan
Bristol Myers boosts cell therapy production with Novartis plant
BioPharma Dive
Wed, 04/26/23 - 05:40 pm
Tags:
Bristol Myers Squibb, cell therapy, Novartis, drug manufacturing
Novartis Culls 10% of Pipeline, Doubles Down on Five Core Therapeutic Areas
BioSpace
Wed, 04/26/23 - 10:24 am
Tags:
Novartis, earnings, solid tumors, hematology, immunology, Neuroscience, cardiovascular disease
Point looks to turn the tables on Novartis
EP Vantage
Wed, 04/26/23 - 09:55 am
Tags:
Novartis, Point Biopharma, radiopharmaceuticals
Novartis, helped by cost cuts, raises full-year outlook
Reuters
Tue, 04/25/23 - 10:47 am
Tags:
Novartis, earnings
Novartis strikes $425M deal with 3BP for FAP-targeting peptide technology
Medical Marketing and Media
Tue, 04/25/23 - 10:32 am
Tags:
Novartis, 3B Pharmaceuticals, FAP-targeting peptides
Novartis plant cleared to produce in-demand cancer drug
BioPharma Dive
Mon, 04/24/23 - 10:59 pm
Tags:
Novartis, drug manufacturing, Pluvicto, New Jersey, cancer, radiopharmaceuticals
FDA again delays Daiichi's plans to challenge Astellas and Novartis for blood cancer market
Fierce Biotech
Fri, 04/21/23 - 10:08 am
Tags:
Daiichi Sankyo, Astellas, Novartis, quizartinib, FDA, blood cancer
Big pharma holds steady on research spending
EP Vantage
Fri, 04/21/23 - 10:03 am
Tags:
R&D, AbbVie, Amgen, AstraZeneca, Bayer, Biogen, Bristol Myers Squibb, Eli Lilly, Gilead Sciences, GSK, JNJ, Merck, Merck KGaA, Moderna Therapeutics, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche, Sanofi, UCB, Vertex Pharmaceuticals
Big pharma’s biggest spenders revealed: 2022 edition
EP Vantage
Fri, 04/21/23 - 10:00 am
Tags:
M&A, R&D, AbbVie, AstraZeneca, Bristol Myers Squibb, Eli Lilly, GSK, JNJ, Merck, Novartis, Pfizer, Roche, Sanofi
AACR 2023 – Hippo makes a splash
EP Vantage
Wed, 04/19/23 - 10:07 am
Tags:
Vivace Therapeutics, VT3989, AACR, Novartis, Sanofi, Ikena Oncology
Double whammy: Supreme Court slaps down separate bids from Novartis, Sanofi
Fierce Pharma
Tue, 04/18/23 - 09:58 am
Tags:
legal, Supreme Court, Novartis, Gilenya, Sanofi, Viatris, EpiPens
In upcoming skin disease clash, doctors see Novartis' Cosentyx as an underdog
Fierce Pharma
Tue, 04/11/23 - 10:04 am
Tags:
Novartis, Cosentyx, AbbVie, Humira, hidradenitis suppurativa, UCB Pharma
Gene therapy startup Vedere to close two years after launch
BioPharma Dive
Sun, 04/2/23 - 04:20 pm
Tags:
Vedere Bio, Novartis, gene therapy
CHMP gives thumbs-up for Wegovy use in adolescents, along with nine new drug recommendations
Endpoints
Sun, 04/2/23 - 04:17 pm
Tags:
EMA, Europe, CHMP, Wegovy, Novo Nordisk, Bimervax, TG Therapeutics, Eli Lilly, Bristol Myers Squibb, Novartis, AstraZeneca
Bicycle, Novartis Ink Oncology Deal Worth up to $1.7B
BioSpace
Tue, 03/28/23 - 11:30 am
Tags:
Bicycle Therapeutics, Novartis, drug discovery, oncology, radioligand
Top 10 pharma R&D budgets in 2022
Fierce Biotech
Mon, 03/27/23 - 10:21 pm
Tags:
R&D, Roche, JNJ, Merck, Pfizer, Novartis, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Sanofi, AbbVie
Novartis' Kisqali cuts recurrence risk in early-stage breast cancer
BioSpace
Mon, 03/27/23 - 11:27 am
Tags:
Novartis, clinical trials, Kisqali, breast cancer
FDA approves Pharming drug for ultra-rare immunodeficiency disease
Endpoints
Sun, 03/26/23 - 11:16 pm
Tags:
FDA, Pharming, Novartis, leniolisib, APDS
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
CP Wire
Sun, 03/26/23 - 03:44 pm
Tags:
PTC Therapeutics, Novartis, Zolgensma, SMA, Novo Nordisk, Ozempic, obesity, diabetes, Baxter, M&A, Celltrio, Thermo Fisher, Pfizer, Astellas, Xtandi, NIH

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.